

TECHNICAL REPORT

HUMAN T-LYMPHOTROPIC VIRUS TYPE 1: TECHNICAL REPORT

FEBRUARY 2020



HUMAN T-LYMPHOTROPIC VIRUS TYPE 1: TECHNICAL REPORT

FEBRUARY 2020



**World Health
Organization**

Human T-lymphotropic virus type 1: technical report

ISBN 978-92-4-002022-1 (electronic version)

ISBN 978-92-4-002023-8 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Human T-lymphotropic virus type 1: technical report. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout: 400 Communications Ltd.

CONTENTS

| | |
|--|-------------|
| ACKNOWLEDGEMENTS | vi |
| ABBREVIATIONS | vii |
| EXECUTIVE SUMMARY | viii |
| INTRODUCTION | 1 |
| Background | 1 |
| WHO global consultation | 1 |
| 1. GLOBAL AND REGIONAL EPIDEMIOLOGY OF HTLV-1 | 3 |
| Geographical location and results of HTLV-1 prevalence studies | 4 |
| African Region | 6 |
| Eastern Mediterranean Region | 6 |
| European Region | 7 |
| Region of the Americas | 7 |
| South-East Asia Region | 8 |
| Western Pacific Region | 8 |
| Issues in information on global HTLV-1 occurrence | 8 |
| 2. HTLV-1 TRANSMISSION | 9 |
| Mother-to-child transmission | 9 |
| Sexual transmission | 10 |
| HTLV-1 transmission through blood, blood products and tissue transplantation | 12 |
| Injecting drug use | 12 |
| Other routes of transmission | 12 |
| 3. TESTING FOR HTLV-1 SCREENING AND DIAGNOSIS | 13 |
| Assays used to detect HTLV-1 infection | 13 |
| Sensitivity and specificity of HTLV-1 serology assays | 13 |
| Issues in HTLV-1 diagnosis | 14 |
| Seroconversion and indeterminate test results | 14 |
| Proposed changes to testing strategies for HTLV-1 infection | 14 |
| Cost as a consideration in testing algorithm design | 14 |
| 4. HEALTH EFFECTS OF HTLV-1 INFECTION | 15 |
| ATL | 15 |
| Global overview of ATL | 16 |
| Incidence and risk of ATL among people with HTLV-1 infection | 16 |
| Factors associated with the development of ATL | 16 |
| Issues related to the epidemiology of ATL | 16 |
| HAM/TSP | 18 |
| Incidence and risk of HAM/TSP among people with HTLV-1 infection | 18 |
| Factors associated with development, progression and mortality | 18 |
| Issues related to the epidemiology of HAM/TSP | 18 |

| | |
|---|-----------|
| HAU | 19 |
| Issues related to the epidemiology of HAU | 19 |
| Infective dermatitis | 19 |
| Issues related to the epidemiology of infective dermatitis | 20 |
| HTLV-1 infection, all-cause mortality and other possible disease associations | 20 |
| All-cause mortality | 20 |
| Conditions classified as inflammatory | 20 |
| Respiratory disease | 20 |
| Other potentially inflammatory conditions | 22 |
| Cancer | 22 |
| Infectious diseases | 22 |
| Tuberculosis | 22 |
| Urinary tract infection | 22 |
| <i>Strongyloides</i> hyperinfection syndrome and symptomatic strongyloidiasis | 22 |
| Infectious skin conditions | 23 |
| Other infectious conditions | 23 |
| Other conditions | 23 |
| Issues related to the epidemiology of diseases not associated by definition with HTLV-1 | 23 |
| 5. PREVENTING HTLV-1 TRANSMISSION | 24 |
| Cessation of breastfeeding | 24 |
| Breast-milk freeze-thaw method | 24 |
| Antibody screening among blood donors | 24 |
| Leukoreduction | 24 |
| Vaccine | 24 |
| 6. PHARMACEUTICAL INTERVENTIONS IN MANAGING HTLV-1 INFECTION AND HTLV-1-ASSOCIATED DISEASE | 25 |
| Pharmaceutical interventions for asymptomatic HTLV-1 infection | 25 |
| HIV antiretroviral therapy | 25 |
| Green tea extract | 25 |
| Issues related to managing asymptomatic HTLV-1 infection | 25 |
| Pharmaceutical interventions for ATL | 25 |
| Interferon-based therapy for ATL | 26 |
| Using combination chemotherapy for ATL treatment | 26 |
| Using biological agents for ATL treatment | 26 |
| Allogenic haematopoietic stem cell transplantation for ATL | 27 |
| Issues related to ATL treatment | 27 |
| Pharmaceutical interventions for HAM/TSP | 27 |
| Agents postulated to alter the disease course of HAM/TSP | 28 |
| Corticosteroids | 28 |
| Pulsed methylprednisolone | 28 |

| | |
|--|-----------|
| Prednisolone | 29 |
| Cyclosporin | 29 |
| Heparin | 29 |
| HIV antiretroviral drugs | 29 |
| Interferon-alpha and interferon-beta | 29 |
| Methotrexate | 29 |
| Monoclonal antibodies specific for IL 2 receptor (anti-Tac) | 29 |
| Mogamulizumab | 29 |
| Sodium valproate (valproic acid) | 30 |
| Agents evaluated for symptomatic management in HAM/TSP | 30 |
| Danazol | 30 |
| <i>Lactobacillus</i> | 30 |
| Pentosan polysulfate | 30 |
| Pentoxifylline | 30 |
| Prosultiamine | 30 |
| Vitamin C | 30 |
| Issues related to HAM/TSP treatment | 30 |
| 7. POLICIES AND GUIDELINES FOR PREVENTING HTLV-1 TRANSMISSION AND TREATING PEOPLE WITH HTLV-1-ASSOCIATED DISEASES | 31 |
| HTLV-1 prevention policies and guidelines | 31 |
| Preventing mother-to-child transmission | 31 |
| Blood donor screening | 31 |
| Organ donor screening | 33 |
| National or regional surveillance programmes | 33 |
| International guidance and recommendations | 33 |
| HTLV-1 testing: who to test and when | 33 |
| Summary of country-specific HTLV-1 testing guidelines | 33 |
| ATL and HAM/TSP treatment guidelines | 34 |
| Conclusion | 34 |
| CONCLUSIONS AND RECOMMENDATIONS OF THE WHO GLOBAL CONSULTATION ON HTLV-1 | 35 |
| Geographical distribution and surveillance | 35 |
| Testing strategies for HTLV-1 infection | 35 |
| HTLV-1 transmission and prevention | 35 |
| Health effects, burden of disease and treatment | 36 |
| General | 36 |
| REFERENCES | 37 |

ACKNOWLEDGEMENTS

Literature review and writers

WHO commissioned the Kirby Institute, University of New South Wales, Sydney, Australia to write this document, based on a series of literature reviews and discussions held during the WHO Global Consultation on HTLV-1 on 13–15 November 2019. The review and writing team included: **Sahar Bajis**, **Rowena Bull**, **Louise Causer**, **John Kaldor**, **Nicolas Legrand**, **Marianne Martinello**, **Skye McGregor**, **Ela Naruka**, **Amrita Ronnachitand** and **Braulio Valencia** (Kirby Institute); and **Nicola Low** (University of Berne, Switzerland).

External review group

The following group of external experts participated in the WHO Global Consultation on HTLV-1 and/or reviewed the series of background documents and this technical report: **Stephen Ayisi Addo** (Ministry of Health, Ghana), **Ali Bazarbachi** (American University of Beirut, Lebanon), **Kristy Blakeborough-Wesson** (HTLVAware, United Kingdom), **Rowena Bull** (Kirby Institute, Australia), **Lucas De Toca** (Department of Health, Government of Australia), **Lloyd Einsiedel** (Baker Heart and Diabetes Institute, Australia), **Raman Gangakhedkar** (Indian Council of Medical Research, India), **Antoine Gessain** (Institut Pasteur, France), **Nano Gideon** (National Department of Health, Papua New Guinea), **Eduardo Gotuzzo** (Universidad Peruana Cayetano Heredia, Peru), **Mohammad Mehdi Gouya** (Iranian Center for Disease Control, Islamic Republic of Iran), **Isao Hamaguchi** (National Institute of Infectious Diseases, Japan), **Olivier Hermine** (Hôpital Necker, France), **Hajime Inoue** (National Center for Global Health and Medicine, Japan), **Masaka Iwanaga** (Nagasaki University Graduate School

Brendan Murphy (Department of Health, Government of Australia), **Edward Murphy** (University of California, San Francisco, USA), **Adriana Necula** (National Institute for Blood Transfusion, Romania), **Sarah Norris** (Department of Health, Government of Australia), **Damian Purcell** (Doherty Institute for Infection and Immunity, Australia), **Araoye Segilola** (National AIDS, STI and Hepatitis Control Programme, Nigeria), **Satoshi Shimada** (Ministry of Health, Labour and Welfare, Japan), **Yasuhiro Suzuki** (Ministry of Health, Labour and Welfare, Japan), **Yutaka Tagaya** (Global Virus Network, USA), **Mai Taki** (Rakuwakai Kyoto Healthcare Center, Japan), **Graham Taylor** (Imperial College London, United Kingdom), **Tamami Umeda** (National Institute of Infectious Diseases, Japan), **Toshiki Watanabe** (International Retrovirology Association and University of Tokyo, Japan), **Lucas Willems** (University of Liège, Belgium), **Yoshihisa Yamano** (St. Marianna University School of Medicine, Japan) and **Yuta Yokobori** (Ministry of Health, Labour and Welfare, Japan).

WHO HTLV-1 Steering Group

A WHO steering group was established to plan for the WHO Global Consultation on HTLV-1 and provide input into this technical report. This work was led by **Andrew Ball** (Department of HIV and Global Hepatitis Programme). Members of the Steering Group included: **Marc Bulterys** (Global Hepatitis Programme), **Ian Cree** (International Agency for Research on Cancer), **Shona Dalal** (Department of HIV), **Meg Doherty** (Department of HIV), **Catherine De Martel** (International Agency for Research on Cancer), **Massimo Ghidinelli** (WHO Regional Office for the Americas), **Anup Gurung** (WHO Country Office in Papua New Guinea), **André Ilbawi** (Department of Management of Noncommunicable Diseases), **Noreen Jack** (WHO Country

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24059

